5 Summary
(1) Official in charge of disbursement of the procuring entity : Akitoshi Yoshida, President, Asahikawa Medical University
(2) Classification of the products to be procured : 4
(3) Nature and quantity of the products to be purchased :
A Cetuximab (Genetical Recombination) (100mg／1vial) 879 vials
B Agalsidase Alfa (Genetical Recombination) (3.5mg／1vial) 184 vials
C Eculizumab (Genetical Recombination) (300mg／1vial) 143 vials
D Pertuzumab (Genetical Recombination) (420mg／14mL／1vial) 147 vials
E Eribulin Mesilate (1mg／1vial) 415 vials
F Rituximab (Genetical Recombination) (500mg／mL／1vial) 305 vials
G Dexmedetomidine Hydrochloride (200μg／5vials／1case) 1,170 cases
H Alglucosidase Alfa (Genetical Recombination) (50mg／1vial) 530 vials
I Denosumab (Genetical Recombination) (120mg／1vial) 822 vials
J fulvestrant (250mg／2vials／1case) 255 cases
K Sugammadex Sodium (200mg／10vials／1case) 384 cases
L Pomalidomide (4mg／7capsules／1case) 162 cases
M Ustekinumab (Genetical Recombination) (45mg／1vial) 186 vials
N Tocilizumab (Genetical Recombination) (400mg／1vial) 261 vials
O Trastuzumab Emtansine (Genetical Recombination) (100mg／1vial) 119 vials
P Pegfilgrastim (Genetical Recombination) (3.6mg／1vial) 299 vials
Q Human fibrinogen Human thrombin (9.5cm×4.8cm／1sheet) 411 sheets
R Micafungin Sodium (50mg／10vials／1case) 319 cases
S Lenalidomide Hydrate (5mg／40capsules／1case) 184 cases
T Palonosetron Hydrochloride (0.75mg／5vials／1case) 415 cases
U Ranibizumab (Genetical Recombination) (10mg／mL／1vial) 351 vials
V Nivolumab (Genetical Recombination) (20mg／1vial) 459 vials
W Nivolumab (Genetical Recombination) (100mg／1vial) 327 vials
X Goserelin Acetate (10.8mg／1syringe) 589 syringes
Y Aflibercept (Genetical Recombination) (40mg／mL／1vial) 763 vials
Z Paclitaxel (100mg／1vial) 707 vials
AA Bortezomib (3mg／1vial) 181 vials
AB Infliximab (Genetical Recombination), Remicade for I.V. Infusion 100 or its equivalent or its equivalent (100mg／1vial) 3,430 vials
AC Brentuximab Vedotin (Genetical Recombination) (50mg／1vial) 55 vials
AD Pemetrexed Sodium Hydrate (100mg／1vial) 431 vials
AE Pemetrexed Sodium Hydrate (500mg／1vial) 175 vials
AF Alectinib Hydrochloride (150mg／28capsules／1case) 124 cases
AG Infliximab (Genetical Recombination), Infliximab BS for I.V. Infusion 100mg 「NK」 or its equivalent or its equivalent (100mg／1vial) 798 vials
AH Landiolol Hydrochloride (150mg／5vials／1case) 275 cases
AI Abatacept (Genetical Recombination) (250mg／1vial) 360 vials
AJ Pembrolizumab (Genetical Recombination) (100mg／4ml／1vial) 230 vials
AK Ramucirumab (Genetical Recombination) (100mg／10ml／1vial) 415 vials
AL Ramucirumab (Genetical Recombination) (500mg／50ml／1vial) 158 vials
AM Golimumab (Genetical Recombination) (50mg／0.5ml／1vial) 301 vials
AN Nusinersen Sodium (12mg／5ml／1vial) 2 vials
AO Somatropin (Genetical Recombination) (10mg／1vial) 327 vials
AP Panitumumab (Genetical Recombination) (400mg／20ml／1vial) 68 vials
AQ Botulinum Toxin Type A (100units／1vial) 215 vials
AR Thrombomodulin Alfa (Genetical Recombination) (12800units／10vials／1case) 72 cases
AS Ruxolitinib Phosphate (5mg／20tablets／1case) 222 cases
AT Secukinumab (Genetical Recombination) (150mg／1kit) 222 kits
AU Adalimumab (Genetical Recombination) (40mg／0.4ml／1syringe) 255 syringes
AV Trastuzumab (Genetical Recombination) (60mg／1vial) 1,236 vials
AW Trastuzumab (Genetical Recombination) (150mg／1vial) 928 vials
AX Agalsidase Beta (Genetical Recombination) (5mg／1vial) 304 vials
AY Agalsidase Beta (Genetical Recombination) (35mg／1vial) 31 vials
AZ Bevacizumab (Genetical Recombination) (100mg／4mL／1vial) 748 vials
BA Bevacizumab (Genetical Recombination) (400mg／16mL／1vial) 578 vials
BB Palivizumab (Genetical Recombination) (50mg／1vial) 207 vials
BC Palivizumab (Genetical Recombination) (100mg／1vial) 318 vials
(4) Delivery period : From 1 May, 2018 through 31 March, 2019
(5) Delivery place : Asahikawa Medical University
(6) Qualifications for participating in the tendering procedures : Suppliers eligible for participating in the proposed tender are those who shall :
A not come under Article 4 and 5 of the Regulation concerning the Contract for Asahikawa Medical University Furthermore, minors, Person under Conservatorship or Person under Assistance that obtained the consent necessary for concluding a contract may be applicable under cases of special reasons within the said clause,
B have the Grade A, Grade B or Grade C qualification during fiscal 2018 in the Hokkaido area in sales of product for participating in tenders by Single qualification for every ministry and agency,
C prove to have obtained the first-class license for selling drugs in accordance with the Law on Securing Quality, Efficacy and Safety of Products including Pharmaceuticals and Medical Devices,
D not be currently under a suspension of business order as instructed by President, Asahikawa Medical University.
(7) Time limit of tender : 17 : 00　13 April, 2018
(8) Contact point for the notice : Tetsuya Hashiba, Procurement Section, Accounting Division, Asahikawa Medical University, 2—1—1—1 Midorigaokahigashi, Asahikawa-shi, Hokkaido, 078—8510 Japan, TEL 0166—69—3068

入札公告

次のとおり一般競争入札に付します。
平成30年2月21日
国立大学法人東京大学総長　五神　真
◎調達機関番号　415　◎所在地番号　13
○第78号
1　調達内容
(1)　品目分類番号　24
(2)　購入等件名及び数量
A　３Ｄ画像構築用電界放出形走査電子顕微鏡システム　一式
B　自動細胞解析装置　一式
(3)　調達件名の特質等　入札説明書による。
(4)　納入期限　平成30年７月31日
(5)　納入場所　東京大学大学院医学系研究科・医学部